<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Microbiology and therapy of peritonitis in peritoneal dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Microbiology and therapy of peritonitis in peritoneal dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Microbiology and therapy of peritonitis in peritoneal dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Burkart, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Osama El Shamy, MD, FASN, FNKF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael S Calderwood, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peritonitis is one of the major complications of peritoneal dialysis and remains the primary reason that patients switch from peritoneal dialysis to hemodialysis [<a href="#rid1">1,2</a>]. This topic reviews the microbiology and therapy of peritonitis in peritoneal dialysis. Risk factors, prevention, and the approach to the diagnosis of peritonitis, including exclusion of other intra-abdominal diseases, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1867.html" rel="external">"Risk factors and prevention of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>The vast majority of peritonitis cases are caused by bacteria. Approximately 3 to 5 percent are caused by fungi, mostly <em>Candida</em> spp [<a href="#rid3">3-5</a>]. A viral etiology of peritonitis has been postulated in some cases, although viral infection as a cause of peritonitis has not been proven conclusively [<a href="#rid6">6</a>].</p><p>Approximately 45 to 65 percent of cases are caused by gram-positive organisms and 15 to 35 percent by gram-negative organisms [<a href="#rid4">4,5,7-10</a>]. More than one organism has been reported in 1 to 4 percent of cases [<a href="#rid3">3,4</a>]. (See <a class="local">'Polymicrobial peritonitis'</a> below.)</p><p>Failure to identify an organism is common. Two series reported 20 to 40 percent of cases that were culture negative [<a href="#rid3">3,4,11</a>]; in the later series, the high percentage may have reflected failure to obtain a peritoneal dialysate sample prior to initiation of antibiotic treatment [<a href="#rid4">4</a>] (See <a class="local">'Culture-negative peritonitis'</a> below.)</p><p>The most common source of peritonitis is intraluminal contamination; typically, this occurs if the patient uses suboptimal sterile technique for connecting or disconnecting the catheter when performing exchanges ("touch contamination"). Other sources of peritonitis include periluminal contamination (due to extension of bacteria from an exit-site or tunnel infection), visceral contamination (via bacteria from bowel), and, rarely, vaginal contamination. In addition, peritonitis can develop via hematogenous dissemination from a remote source.</p><p>Specific pathogen categories are discussed in greater detail below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram positive</strong> – Common gram-positive pathogens include coagulase-negative <em>Staphylococcus </em>spp, <em>Streptococcus </em>spp,<em> Staphylococcus aureus, Enterococcus </em>spp, and<em> Corynebacterium </em>spp.</p><p></p><p class="bulletIndent1">Coagulase-negative <em>Staphylococcus</em> is the most common cause of peritonitis. In one of the more recent studies, coagulase-negative staphylococci<em> </em>caused 60 percent of infections caused by gram-positive organisms and 39 percent of infections overall [<a href="#rid10">10</a>]. <em>Streptococcus </em>spp caused 20 percent of gram-positive infections and 13 percent of infections overall. <em>S. aureus, Enterococcus </em>spp, and <em>Corynebacterium </em>spp caused 6, 6, and 4 percent of gram-positive infections, respectively, and 4, 4, and 2.5 percent of infections overall.</p><p></p><p class="bulletIndent1">The relative percentages of peritonitis caused by different <em>Staphylococcus</em> spp have changed over time [<a href="#rid4">4,9</a>]. The use of Y systems (or flush before fill) reduced the overall incidence of peritonitis [<a href="#rid12">12,13</a>], predominantly by decreasing touch contamination-associated infections due to coagulase-negative staphylococcus [<a href="#rid4">4</a>]. Because Y systems did not reduce the incidence of <em>S. aureus</em> peritonitis to the same degree, the relative proportion of staphylococcal peritonitis cases due to <em>S. aureus</em> increased.</p><p></p><p class="bulletIndent1">The frequency of vancomycin-resistant enterococci (VRE) has increased [<a href="#rid14">14</a>]. Major risk factors include prior exposure to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> and cephalosporins. (See  <a class="medical medical_review" href="/d/html/4045.html" rel="external">"Vancomycin-resistant enterococci: Epidemiology, prevention, and control"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram negative</strong> – Gram-negative organisms can be from the bowel, skin, urinary tract, contaminated water, or animal contact [<a href="#rid15">15,16</a>]. In some centers, effective measures to prevent touch contamination and reduce the incidence of peritonitis cases caused by gram-positive organisms have led to an increase in the relative proportion, but not incidence, of peritonitis cases caused by gram-negative organisms [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/1867.html" rel="external">"Risk factors and prevention of peritonitis in peritoneal dialysis", section on 'Prevention'</a> and  <a class="medical medical_review" href="/d/html/1888.html" rel="external">"Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1">Common causes of gram-negative peritonitis include <em>Escherichia coli, Klebsiella </em>spp,<em> </em>and<em> Pseudomonas aeruginosa</em> (33, 25, and 12 percent of the gram-negative infections in one study, respectively) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fungal</strong> – Fungal peritonitis is uncommon in peritoneal dialysis patients. The presenting signs and symptoms associated with fungal peritonitis are similar to those seen with bacterial peritonitis. The approach to such patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1">Fungal infection is an indication for immediate catheter removal. (See <a class="local">'Indications for catheter removal'</a> below.)</p><p></p><p class="headingAnchor" id="H2303266792"><span class="h1">DETERMINING THE SITE OF CARE</span><span class="headingEndMark"> — </span>Most patients with peritoneal dialysis-associated peritonitis should be managed in the outpatient setting  (<a class="graphic graphic_algorithm graphicRef143367" href="/d/graphic/143367.html" rel="external">algorithm 1</a>). Indications for inpatient treatment include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis</p><p class="bulletIndent1"><span class="glyph">●</span>Severe abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Inability to administer intraperitoneal antibiotic therapy at home</p><p class="bulletIndent1"><span class="glyph">●</span>Unavailability of appropriate antibiotic agents in the outpatient setting</p><p></p><p class="headingAnchor" id="H15676597"><span class="h1">ANTIMICROBIAL THERAPY</span><span class="headingEndMark"> — </span>The major treatment for peritoneal dialysis-associated peritonitis is antimicrobial therapy. Antibiotic treatment recommendations are based on expert opinion; systematic reviews have shown no single, optimal antibiotic agent or combination of agents [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H12884851"><span class="h2">Route of administration</span></p><p class="headingAnchor" id="H1338346089"><span class="h3">Intraperitoneal administration (preferred)</span><span class="headingEndMark"> — </span>Intraperitoneal administration of antibiotics is preferred to intravenous administration, unless the patient appears septic or has other indications for systemic antibiotics, as discussed below [<a href="#rid20">20-22</a>]. (See <a class="local">'Oral or intravenous administration'</a> below.)</p><p>Intraperitoneal administration provides optimal local antibiotic concentration. In the majority of patients, infection is localized to the peritoneum and a few cell layers lining the peritoneal cavity and intra-abdominal viscera. Commonly used antibiotics, including <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, cephalosporins, and aminoglycosides, can be mixed in the same dialysis bag without loss of bioactivity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous versus intermittent dosing</strong> – Intraperitoneal antibiotics can be administered either continuously (with antibiotics given in each exchange) or intermittently (given once daily for almost all antibiotics, with a few exceptions where every other bag dosing is recommended). We initiate therapy with intermittent dosing for ease-of-use reasons, though occasionally switch to continuous dosing if the patient does not respond to intermittent dosing (see <a class="local">'Monitoring clinical response'</a> below). However, many clinicians initiate therapy with continuous dosing. Continuous and intermittent intraperitoneal dosing regimens have similar rates of treatment failure and relapse [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Intraperitoneal antibiotics that are administered intermittently must dwell for at least six hours  (<a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>). For patients on continuous ambulatory peritoneal dialysis (CAPD), intermittent antibiotics are typically administered during the overnight dwell, whereas for patients on automated peritoneal dialysis (APD) intermittent antibiotics are administered during the longest daytime dwell.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Considerations for APD</strong> – Specific considerations apply to patients on APD. When patients set up their cycler, they will connect two or three bags of fluid for the overnight dwells, some of which may be used for the daytime dwell(s), and then often attach a different bag of fluid to be used for the daytime dwell(s). The typical daytime dwell often uses a different dialysate bag (different percent dextrose or <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>) than the overnight dwells. As a result, if the clinician is prescribing intermittent dosing, then the prescribed antibiotic should be added to the daytime dwell that is intended to dwell at least six hours. If the clinician wishes to use continuous dosing, the clinician and home training team need to remember that after the first overnight fill, the cycler draws fluid from all the overnight bags. Thus, when continuous dosing in APD is used, it is important to add antibiotics in the dose concentration (usually dosed in mg/L  (<a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>)) to all bags.</p><p></p><p class="headingAnchor" id="H2708512663"><span class="h3">Oral or intravenous administration</span><span class="headingEndMark"> — </span>For patients with sepsis, bacteremia, or a visceral source of infection (eg, intra-abdominal process), intravenous antibiotics are usually necessary. Intravenous administration is also appropriate for initial therapy when immediate administration of intraperitoneal antibiotics is not possible, with a transition to intraperitoneal route once available. (See <a class="local">'Timing'</a> below.)</p><p>Oral or intraperitoneal antibiotics can be used as step-down therapy for patients on intravenous antibiotics once they have stabilized. Oral antibiotics can also be used when intraperitoneal administration of the necessary antibiotic is not an option.</p><p>For patients whose peritonitis is treated with systemic antibiotics (ie, oral or intravenous), concomitant intraperitoneal antibiotic administration is typically unnecessary.</p><p class="headingAnchor" id="H2368025374"><span class="h2">Monitoring drug levels</span><span class="headingEndMark"> — </span>For <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> and aminoglycosides, we typically monitor serum drug levels to facilitate dosing and prevent toxicity since systemic absorption occurs with intraperitoneal antibiotic administration. Monitoring serum levels of these antibiotics may be especially useful in patients with greater degrees of residual kidney function who may excrete substantial amounts of these agents in the urine.</p><p>However, this practice is not universal, and some clinicians do not monitor drug levels.</p><p class="headingAnchor" id="H933714024"><span class="h2">Role of antifungal prophylaxis</span><span class="headingEndMark"> — </span>Treatment with intraperitoneal or systemic antibiotics is a major risk factor for the development of fungal peritonitis among peritoneal dialysis patients. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis", section on 'Causes and risk factors'</a>.)</p><p>Antifungal prophylaxis during the course of antibiotic therapy may reduce the risk of subsequent fungal peritonitis. There is no consensus on the optimal approach to prevention of fungal peritonitis [<a href="#rid23">23</a>]. We administer antifungal prophylaxis among patients on peritoneal dialysis who are treated with antibiotics for longer than three days, regardless of the site of infection. However, others favor administration of antifungal prophylaxis with any antibiotic course lasting longer than one day [<a href="#rid24">24-31</a>]. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a>.)</p><p>Issues related to selection and dosing of antifungal prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Initial empiric therapy</span><span class="headingEndMark"> — </span>The initial empiric antibiotic regimen should be selected based on local sensitivity data for organisms that commonly cause peritonitis [<a href="#rid22">22,32,33</a>] and whether a patient has recently received antimicrobial therapy for another indication. Past culture results, including cultures from sites other than peritoneal fluid, should also be reviewed to assess whether a broader regimen is appropriate.</p><p class="headingAnchor" id="H3056107671"><span class="h3">Timing</span><span class="headingEndMark"> — </span>Empiric antibiotics should be initiated as soon as possible after peritoneal fluid specimens are obtained for cell count, Gram stain, and culture  (<a class="graphic graphic_algorithm graphicRef143367" href="/d/graphic/143367.html" rel="external">algorithm 1</a>) [<a href="#rid22">22</a>]. Most patients with peritonitis should be treated with intraperitoneal antibiotics (see <a class="local">'Route of administration'</a> above); however, in cases where the immediate administration of intraperitoneal antibiotics may not be possible (eg, in an emergency department or inpatient setting lacking staff trained in peritoneal dialysis), intravenous antibiotics should be administered to avoid lengthy delays in treatment. Patients with peritonitis receiving intravenous antibiotics due to anticipated delays in intraperitoneal antibiotic delivery should be switched from intravenous to intraperitoneal antibiotics as soon as it is feasible to do so. (See <a class="local">'Oral or intravenous administration'</a> above.)</p><p>The importance of prompt antibiotic administration was illustrated by an observational study of 116 patients with peritoneal dialysis-associated peritonitis [<a href="#rid34">34</a>]. In patients who presented to the hospital with peritonitis, every hour of delay in administering antimicrobial therapy was associated with a 6.8 percent increase in the risk of peritoneal dialysis failure or death.</p><p class="headingAnchor" id="H1579101026"><span class="h3">Selection of empiric antibiotics</span><span class="headingEndMark"> — </span>For initial therapy, we treat with a broad-spectrum antibiotic regimen that covers both gram-positive and gram-negative organisms [<a href="#rid20">20-22,35</a>]. As described above, we provide antifungal prophylaxis to patients who receive antibiotics for longer than three days. (See <a class="local">'Role of antifungal prophylaxis'</a> above.)</p><p class="headingAnchor" id="H3392136928"><span class="h4">Preferred regimen</span><span class="headingEndMark"> — </span>We generally use the following antibiotic regimen for initial empiric therapy  (<a class="graphic graphic_table graphicRef143362" href="/d/graphic/143362.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> <strong>plus</strong> intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> (see tables for dosing  (<a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>))</p><p></p><p>However, prior to initiating empiric antibiotics, patients’ past culture results should be reviewed to assess whether a broader regimen is appropriate. (See <a class="local">'Alternative regimens'</a> below.)</p><p>For gram-positive coverage, we typically use intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> because the majority of coagulase-negative staphylococci are resistant to beta-lactams and because vancomycin covers methicillin-resistant <em>S. aureus </em>(MRSA), a pathogen that has been associated with worse outcomes [<a href="#rid36">36,37</a>]. However, in centers where MRSA rates are low, some experts suggest that intraperitoneal <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> can be used instead of vancomycin since many coagulase-negative staphylococci reported as resistant to beta-lactams may be susceptible at the high cefazolin concentrations achieved in peritoneal fluid [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2448490257"><span class="h4">Alternative regimens</span><span class="headingEndMark"> — </span>Alternative empiric regimens may be necessary due to antibiotic intolerance or suspicion of an antibiotic-resistant organism. Intraperitoneal dosing of these regimens is listed in the tables  (<a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>).</p><p>For gram-positive coverage, intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> is usually adequate. However, for patients with prior vancomycin-resistant enterococcal infection, intravenous <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>, or oral or intravenous <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, is appropriate.</p><p>For gram-negative coverage, we favor intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> because it has been shown to be effective in numerous studies, including studies of patients on CAPD and APD. Empiric intraperitoneal <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> has been shown to be noninferior to standard of care in two small, randomized studies comparing outcomes of cefepime monotherapy with <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> plus ceftazidime and <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> plus netilmicin, but we continue to use ceftazidime because of the volume of evidence supporting it use [<a href="#rid22">22,38,39</a>]. Other cephalosporins (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, cefazolin) have a narrower gram-negative spectrum than ceftazidime and cefepime (eg, ceftriaxone does not cover <em>Pseudomonas </em>spp).</p><p>If prior culture results suggest that an infection due to a multidrug-resistant gram-negative organism (eg, extended-spectrum beta-lactamase [ESBL]-producing bacteria) is possible, cephalosporins are often not appropriate. Other options include intraperitoneal carbapenems (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>), oral or intraperitoneal fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>), or intraperitoneal aminoglycosides (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>)  (<a class="graphic graphic_table graphicRef143362" href="/d/graphic/143362.html" rel="external">table 3</a>). These antibiotics are also often options in patients who report serious penicillin allergies, although cephalosporins can often be safely administered to these patients. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a>.)</p><p>Despite the convenience of oral dosing of fluoroquinolones, we generally try to avoid fluoroquinolones because they have significant adverse effects, increase the risk of <em>Clostridioides</em> <em>difficile </em>infection, and have numerous drug interactions (including oral phosphate binders) [<a href="#rid40">40</a>]. We also try to avoid aminoglycosides because they can cause ototoxicity, even when given intraperitoneally [<a href="#rid22">22</a>]. (See <a class="local">'Monitoring drug levels'</a> above.)</p><p>If the Gram stain reveals yeast or other fungus, antifungal agents should be started and the patient should be prepared for possible catheter removal depending on the final culture results; fungal infection is an indication for prompt catheter removal [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a>.)</p><p>Overall, our antibiotic approach is in agreement with the 2022 International Society for Peritoneal Dialysis (ISPD) guidelines [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Subsequent therapy</span><span class="headingEndMark"> — </span>Results of peritoneal fluid cultures and antimicrobial susceptibility testing should be used to tailor the antibiotic regimen, if appropriate. In many cases, the broad-spectrum empiric regimen can be replaced by a more narrow-spectrum agent [<a href="#rid22">22</a>].</p><p>We also provide antifungal prophylaxis to all patients with confirmed peritonitis, as described above. (See <a class="local">'Role of antifungal prophylaxis'</a> above.)</p><p class="headingAnchor" id="H1688102460"><span class="h3">Single bacterial organism</span><span class="headingEndMark"> — </span>The antimicrobial regimen should be narrowed after a specific susceptible organism is identified [<a href="#rid22">22</a>] and may be further adjusted based on clinical response [<a href="#rid20">20-22,36,41-43</a>]. Although most pathogens can be effectively treated with a single agent, we treat some organisms with dual antibiotic therapy. Antibiotic administration is detailed elsewhere in this topic review, and intraperitoneal dosing is outlined in the tables  (<a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>). (See <a class="local">'Route of administration'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic regimen(s) for gram-positive infections </strong>– For gram-positive infections, we favor the antibiotic with the narrowest spectrum.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coagulase-negative staphylococci </strong>–<strong> </strong>Infections due to these organisms often require intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>. The exception is methicillin-susceptible isolates, which can typically be treated with intraperitoneal <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a>  (<a class="graphic graphic_algorithm graphicRef143368" href="/d/graphic/143368.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>). We treat initial infections for at least 14 days; for patients with recurrent infection, we treat for at least 21 days. If the catheter is removed, we ensure at least 14 days of systemic antibiotics are received after catheter removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>S. aureus</em></strong><strong> </strong>– Patients with cultures demonstrating methicillin-resistant <em>S. aureus</em> warrant treatment with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>; patients with methicillin-sensitive <em>S. aureus</em> should be treated with a first-generation cephalosporin, such as <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a>  (<a class="graphic graphic_algorithm graphicRef143368" href="/d/graphic/143368.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2">We typically add oral <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for the first five to seven days of therapy for patients with <em>S. aureus </em>peritonitis, because some data suggest that rifampin may decrease recurrences and the drug is known to penetrate biofilms, as discussed separately [<a href="#rid36">36</a>] (see  <a class="medical medical_review" href="/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment", section on 'Use of adjunctive rifampin'</a>). However, the addition of rifampin is not a universal practice, and some reserve its use for patients with inadequate response to initial therapy. (See  <a class="medical medical_review" href="/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment", section on 'Use of adjunctive rifampin'</a>.)</p><p></p><p class="bulletIndent2">We treat for at least 21 days, and, for patients whose catheter is removed due to infection, we ensure at least 14 days of systemic antibiotics are administered from the date of catheter removal. Patients who also have <em>S. aureus </em>bacteremia require prolonged intravenous therapy, as discussed separately. (See  <a class="medical medical_review" href="/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Streptococcus </em></strong><strong>species </strong>–<strong> </strong>Intraperitoneal <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> is appropriate for infections caused by these organisms. Streptococcal isolates that are not tested for susceptibility can generally be assumed to be susceptible to penicillins and cephalosporins  (<a class="graphic graphic_algorithm graphicRef143369" href="/d/graphic/143369.html" rel="external">algorithm 3</a> and <a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2">We treat for at least 14 days, and, for patients whose catheter is removed due to infection, we ensure that 14 days of systemic antibiotics are administered from the date of catheter removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Enterococcus</em></strong><strong> species </strong>– We typically treat ampicillin-susceptible enterococci with intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>; some experts recommend oral <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> for these patients, but we favor intraperitoneal antibiotics over oral options because intraperitoneal antibiotics achieve reliably high concentrations in peritoneal fluid (see <a class="local">'Intraperitoneal administration (preferred)'</a> above). We favor vancomycin over <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> because some in vitro data suggest that the activity of ampicillin against enterococci may be limited in peritoneal fluid  (<a class="graphic graphic_algorithm graphicRef143366" href="/d/graphic/143366.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2">Infection with vancomycin-resistant <em>Enterococcus</em> (VRE) is often treated with intraperitoneal <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> or oral <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>. We generally favor intraperitoneal daptomycin over oral linezolid because of toxicity-related issues and our general preference for intraperitoneal antibiotics over oral options. We suggest consultation with an infectious disease specialist for VRE peritonitis.</p><p></p><p class="bulletIndent2">We treat for at least 21 days, and, for patients whose catheter is removed due to infection, we ensure at least 14 days of systemic antibiotics are administered from the date of catheter removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Corynebacterium </em></strong><strong>species </strong>–<strong> </strong>Infections due to these organisms typically require intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> for a total of 14 days  (<a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic regimens for gram-negative infections </strong>–<strong> </strong>Gram-negative pathogens can be difficult to treat and may require antibiotics associated with significant toxicity or other side effects. In general, we try to avoid fluoroquinolones and aminoglycosides for the reasons described above. (See <a class="local">'Alternative regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Pseudomonas</em></strong><strong> species </strong>– Because <em>Pseudomonas</em> peritonitis has a low cure rate [<a href="#rid45">45,46</a>], we treat Pseudomonas infections with two antibiotics with different mechanisms of action, such as intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> plus either oral <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or intraperitoneal aminoglycoside (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>). Details regarding treatment of pseudomonal infections are found elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p></p><p class="bulletIndent2">We treat pseudomonal infections for at least 21 days, and, for patients whose catheter is removed due to infection, we ensure at least 14 days of systemic antibiotics are administered from the date of catheter removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Acinetobacter</em></strong><strong> species </strong>– Drug-resistant <em>Acinetobacter</em> peritonitis is an increasing problem worldwide, and often has a low cure rate [<a href="#rid47">47</a>]. We typically treat <em>Acinetobacter</em> infections with a single agent, based on susceptibility results. For patients with severe illness, we use combination therapy. Details regarding antibiotic selection for <em>Acinetobacter </em>infections can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/3150.html" rel="external">"Acinetobacter infection: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent2">We treat <em>Acinetobacter</em> infections for at least 21 days, and, for patients whose catheter is removed due to infection, we ensure at least 14 days of systemic antibiotics are administered from the date of catheter removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Stenotrophomonas maltophilia</em></strong><strong> </strong>– Peritonitis due to <em>S.</em> <em>maltophilia</em>, a difficult-to-treat organism, is uncommon [<a href="#rid48">48,49</a>]. Based on results of susceptibility testing, we treat <em>S.</em> <em>maltophilia</em> infections with dual antibiotic therapy using oral <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> plus an additional intraperitoneal antibiotic.</p><p></p><p class="bulletIndent2">Details regarding antibiotic selection for <em>Stenotrophomonas </em>infections can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/13961.html" rel="external">"Stenotrophomonas maltophilia", section on 'Suggested antibiotic regimens'</a>.)</p><p></p><p class="bulletIndent2">We treat <em>Stenotrophomonas</em> infections for at least 21 days, and, for patients whose catheter is removed due to infection, we ensure at least 14 days of systemic antibiotics are administered from the date of catheter removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>E. coli </em></strong><strong>and other enteric gram-negative bacilli </strong>– The enteric gram-negative bacilli are becoming increasingly resistant to common antibiotics.</p><p></p><p class="bulletIndent2">In most cases, antibiotic selection should be based on susceptibility results  (<a class="graphic graphic_table graphicRef79841" href="/d/graphic/79841.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef60452" href="/d/graphic/60452.html" rel="external">table 2</a>). Most enteric gram-negative bacilli can be treated with a single agent with the narrowest spectrum that covers the isolate (eg, intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>; oral or intraperitoneal <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>; intraperitoneal aminoglycoside). However, the organisms bulleted below require more nuanced management:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>ESBL-producing isolates </strong>–<strong> </strong>Intraperitoneal carbapenems (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>), oral or intraperitoneal fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>), and intraperitoneal aminoglycosides often remain options for these organisms. Details regarding antibiotic select for ESBL infections are found elsewhere. (See  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases", section on 'Treatment options'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>Enterobacter cloacae </em></strong><strong>complex, </strong><strong><em>Klebsiella aerogenes </em></strong><strong>(formerly </strong><strong><em>Enterobacter aerogenes</em></strong><strong>), </strong><strong><em>Citrobacter freundii</em></strong><strong> </strong>–<strong> </strong>AmpC is a resistance mechanism that is harbored by some gram-negative bacilli that often cannot be detected on standard susceptibility testing. The three listed bacteria are the most common AmpC producers. As such, many experts suggest that these bacteria be presumed to be resistant to all beta-lactam agents except for <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> and carbapenems.</p><p></p><p class="bulletIndent3">For these bacteria, intraperitoneal <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, intraperitoneal carbapenems (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>), oral or intraperitoneal fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>), or intraperitoneal aminoglycosides (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>) can be used if reported as susceptible. All other beta-lactams (eg, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>) are typically ineffective against these organisms even if they are reported as susceptible.</p><p></p><p class="bulletIndent3">Other enteric gram-negative bacilli are often mentioned as possible AmpC producers, but the prevalence of AmpC production in these bacteria is significantly lower than the three bacteria listed above. More information on AmpC producing bacteria is available elsewhere. (See  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Regimen choice'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Carbapenem-resistant Enterobacterales (CRE) </strong>– These are among the most difficult-to-treat organisms, and infectious diseases consultation is suggested. In some cases, oral or intraperitoneal fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>) or intraperitoneal aminoglycosides (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>) may be viable options. Details regarding antibiotic selection for CRE infections are found elsewhere. (See  <a class="medical medical_review" href="/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Approach to treatment'</a>.)</p><p></p><p class="bulletIndent3">We have a low threshold to remove the catheter in patients with confirmed peritonitis due to CRE (see <a class="local">'Indications for catheter removal'</a> below). Catheter removal eliminates the catheter as a nidus of ongoing bacterial replication, thereby reducing the likelihood that resistance will develop while on therapy. Because so few antibiotic options are available for CRE, the consequences of development of resistance while on therapy are much higher. Once standard antibiotic options are exhausted, more toxic agents or newer intravenous extended-spectrum antibiotics become necessary.</p><p></p><p class="bulletIndent2">We treat enteric gram-negative infections for at least 21 days, and, for patients whose catheter is removed due to infection, we ensure at least 14 days of systemic antibiotics are administered from the date of catheter removal.</p><p></p><p class="headingAnchor" id="H1289546702"><span class="h3">Polymicrobial peritonitis</span><span class="headingEndMark"> — </span>Polymicrobial infection (either multiple gram-negative organisms or both gram-positive and gram-negative organisms) has been reported in 1 to 4 percent of cases of peritoneal dialysis-associated peritonitis [<a href="#rid3">3,4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for source </strong>–<strong> </strong>Peritonitis due to multiple enteric organisms or mixed gram-negative/gram-positive organisms should raise concern for a concurrent intra-abdominal condition such as ischemic bowel or diverticular disease. In such cases, imaging studies and surgical consultation should be obtained [<a href="#rid20">20,21,50</a>]. (See  <a class="medical medical_review" href="/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'When to suspect secondary peritonitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic management </strong>–<strong> </strong>Broad-spectrum antimicrobial therapy should include coverage for anaerobes and the types of organisms seen on Gram stain. For patients who have gram-positive and gram-negative organisms on Gram stain, we generally treat with intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, and oral or intravenous <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>. For patients with mixed gram-negative organisms without gram-positive organisms, intraperitoneal vancomycin can usually be omitted from the regimen. Options for gram-negative coverage other than ceftazidime include intraperitoneal <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, intraperitoneal aminoglycoside (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>), intraperitoneal carbapenem (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>), intraperitoneal <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>, or oral or intraperitoneal fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>).</p><p></p><p class="bulletIndent1">Once the organisms are identified, antibiotic coverage should be narrowed to target the pathogens (we switch to a nonaminoglycoside agent to prevent ototoxicity, if possible). If an intra-abdominal process is suspected, we typically continue anaerobic coverage for the full course of therapy even if anaerobic bacteria did not grow on culture. We treat polymicrobial infections for at least 21 days, and, for patients whose catheter is removed due to infection, we ensure at least 14 days of systemic antibiotics are administered from the date of catheter removal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter management </strong>–<strong> </strong>Catheter removal is typically necessary for polymicrobial infections, as discussed below. (See <a class="local">'Indications for catheter removal'</a> below.)</p><p></p><p class="headingAnchor" id="H2144155719"><span class="h3">Culture-negative peritonitis</span><span class="headingEndMark"> — </span>Culture-negative peritonitis is treated with empiric antibiotics and usually has a clinical course that is similar to that of coagulase-negative <em>Staphylococcus</em> infection [<a href="#rid5">5,51,52</a>]. (See <a class="local">'Selection of empiric antibiotics'</a> above and <a class="local">'Microbiology'</a> above.)</p><p>For patients with culture-negative peritonitis after three days of broad spectrum empiric antimicrobial therapy, we assess clinical status and repeat the peritoneal fluid cell count, Gram stain, and culture. Our approach depends on clinical improvement, as determined by an improvement in signs/symptoms and a decrease in cell count  (<a class="graphic graphic_algorithm graphicRef143363" href="/d/graphic/143363.html" rel="external">algorithm 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with clinical improvement</strong> – For patients with clinical improvement after three days of antibiotics, we stop empiric antibiotic coverage of gram-negative organisms. Provided cultures continue to show no growth, we continue empiric gram-positive coverage (eg, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>) for a total of two weeks (see <a class="local">'Selection of empiric antibiotics'</a> above). Many cases of culture-negative peritonitis that improve with empiric therapy are likely caused by gram-positive organisms (eg, coagulase-negative staphylococci).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without clinical improvement</strong> – For patients without clinical improvement after three days of antimicrobial therapy, we perform specific cultures for <em>Mycobacteria</em>, fungal organisms, and <em>Nocardia</em>. Additional management depends on whether the empiric antibiotic regimen includes <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients not treated with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, we switch empiric gram-positive antibiotic coverage to vancomycin and continue existing empiric gram-negative antibiotic coverage.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients treated with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, we continue broad spectrum empiric antibiotics. We also address potential (and uncommon) noninfectious causes of peritonitis by discontinuing exchanges that contain <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> and by reviewing all medications to look for potential allergens. In addition to adverse reactions to icodextrin, noninfectious causes of peritonitis include allergic reactions [<a href="#rid53">53-61</a>]. Icodextrin dialysate-associated peritonitis occurs either immediately or after several months of exposure [<a href="#rid58">58,60,62,63</a>]. (See  <a class="medical medical_review" href="/d/html/1905.html" rel="external">"Peritoneal dialysis solutions", section on 'Glucose polymer-containing solutions (icodextrin)'</a>.)</p><p></p><p class="bulletIndent1">After five days total of antimicrobial therapy (ie, day 6 of antibiotics), we obtain peritoneal fluid for another cell count. In patients without improvement in signs/symptoms or without a decrease in cell count, the catheter should be removed and broad spectrum systemic antibiotics should be continued for at least 14 more days (see <a class="local">'Indications for catheter removal'</a> below). In patients with an improvement in signs/symptoms and a decrease in cell count, our approach is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients whose empiric antibiotic regimen was changed to include <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> after initial empiric therapy without vancomycin, we continue broad spectrum empiric antibiotics for a 14-day course.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients whose initial empiric antibiotic regimen included <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, our approach depends on whether the patient has suspected noninfectious peritonitis (ie, negative cultures in the setting of recent addition of <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> exchanges and/or identification of a potential allergen):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients without suspected noninfectious peritonitis, we continue broad spectrum empiric antibiotics for a 14-day course.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with suspected noninfectious peritonitis, we stop antibiotics and continue to observe. In patients with ongoing symptomatic improvement off antibiotics, we obtain a peritoneal fluid cell count in two weeks to ensure resolution of peritoneal fluid leukocytosis. If patients develop worsening signs/symptoms, we obtain a peritoneal fluid cell count and repeat culture and we resume broad spectrum empiric antibiotics. In such patients, restarting antibiotics should be accompanied by rapid improvement in symptoms and reduction in cell count, in which case we continue the resumed course of antimicrobial therapy for a total of 14 days; otherwise, the peritoneal dialysis catheter should be removed and systemic antibiotics continued for at least an additional 14 days.</p><p></p><p class="bulletIndent1">If a specific organism is identified on culture, the choice and duration of antimicrobial therapy should be adjusted accordingly.</p><p></p><p class="headingAnchor" id="H108783198"><span class="h3">Fungal peritonitis</span><span class="headingEndMark"> — </span>Fungal infection is an indication for immediate catheter removal. (See <a class="local">'Indications for catheter removal'</a> below.)</p><p>Details regarding management of patients with fungal peritonitis are found elsewhere. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H3417804899"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>In general, antibiotics are continued for at least 21 days for patients with <em>S. aureus </em>or enterococcal<em> </em>peritonitis and in all cases of peritonitis due to gram-negative bacilli or polymicrobial infection. Other common skin flora (eg, coagulase-negative staphylococci, <em>Corynebacterium </em>spp) typically respond well to 14 days. If the catheter is removed for infection, we ensure that at least 14 days of systemic therapy are provided after catheter removal.</p><p>Pathogen-specific durations are discussed above. (See <a class="local">'Subsequent therapy'</a> above.)</p><p class="headingAnchor" id="H2137918108"><span class="h1">MONITORING CLINICAL RESPONSE</span><span class="headingEndMark"> — </span>We monitor the patient's clinical response daily to make sure symptoms are stable or starting to improve. Clinical improvement should be observed within 48 hours of initiating therapy [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'Evaluation'</a>.)</p><p>By 48 hours, the fluid should be less cloudy. We repeat cell counts to assess response to therapy [<a href="#rid21">21</a>]. The cell count should be decreasing from baseline obtained on presentation. Methods for obtaining peritoneal fluid and evaluation of cell counts are described elsewhere. (See  <a class="medical medical_review" href="/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis", section on 'Peritoneal fluid analysis'</a>.)</p><p>The absence of substantial improvement in the cell count suggests lack of response to treatment. In a study of 565 consecutive episodes of peritonitis, a persistent dialysate cell count &gt;1000 by the third day of peritonitis was associated with a 64 percent likelihood of treatment failure [<a href="#rid64">64</a>]. In a subsequent study of 644 episodes of peritonitis, patients with eventual treatment failure had a 59 percent reduction in cell count after five days of antibiotics, whereas patients with successful treatment had a ≥89 percent reduction in cell count after five days of antibiotics [<a href="#rid65">65</a>]. Trends in effluent cell counts differ by causative organisms as well as host response [<a href="#rid66">66</a>].</p><p>If the patient's clinical status and/or cell count<strong> </strong>does not appear to be improving by 48 hours and cultures demonstrate a susceptible organism, we take the following steps:</p><p class="bulletIndent1"><span class="glyph">●</span>We switch from intermittent to continuous dosing of intraperitoneal antibiotics [<a href="#rid67">67</a>]. (See <a class="local">'Route of administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For gram-negative infections, we add a second antibiotic based on sensitivities [<a href="#rid68">68,69</a>]. However, there are no good studies that support this practice, and some clinicians prefer to continue with single antibiotic rather than risk the potential toxicity associated with an additional agent.</p><p></p><p>If a cloudy effluent persists after five days of appropriate antibiotic therapy, we remove the catheter [<a href="#rid21">21</a>]. (See <a class="local">'Indications for catheter removal'</a> below.)</p><p class="headingAnchor" id="H2897765884"><span class="h1">INDICATIONS FOR CATHETER REMOVAL</span><span class="headingEndMark"> — </span>In some cases, catheter removal is required to eradicate infection. We remove the catheter in the following circumstances [<a href="#rid20">20,21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Refractory peritonitis, defined as peritonitis without clinical response to appropriate antibiotics within five days. A clinical response consists of improvement in signs/symptoms and a marked reduction in peritoneal fluid cell count. (See <a class="local">'Monitoring clinical response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapsing peritonitis, defined as a repeat episode of peritonitis within four weeks of completion of an antibiotic course. The repeat episode is caused by the same organism that caused the initial episode or follows an episode of culture-negative peritonitis. We may also remove the catheter if the patient develops a repeat episode of peritonitis with the same species within two months of completion of an antibiotic course. (See <a class="local">'Culture-negative peritonitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peritonitis caused by fungal organisms. (See  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peritonitis caused by <em>Mycobacteria</em>, <em>Nocardia, </em>or carbapenem-resistant Enterobacterales (CRE). For peritonitis due to <em>Mycobacterium tuberculosis</em>, though not nontuberculous <em>Mycobacteria</em>, some experts attempt treatment without catheter removal [<a href="#rid22">22</a>]. However, given the high rate of mortality incurred in patients with tuberculous peritonitis [<a href="#rid70">70</a>], we remove the catheter in tuberculous and nontuberculous <em>Mycobacteria</em>-associated peritonitis. The management of infections due to CRE is discussed above (see <a class="local">'Single bacterial organism'</a> above). The management of <em>Mycobacteria</em> and <em>Nocardia</em> is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1238.html" rel="external">"Abdominal tuberculosis"</a> and  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/5513.html" rel="external">"Treatment of nocardiosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peritonitis occurring in association with intra-abdominal pathology, such as an abscess, perforation, or infarcted bowel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Culture-negative peritonitis with persistent symptoms and high peritoneal white blood cell count. (See <a class="local">'Culture-negative peritonitis'</a> above.)</p><p></p><p>The duration of systemic antibiotic therapy after catheter removal is typically at least 14 days, as discussed above. (See <a class="local">'Duration of therapy'</a> above.)</p><p>Simultaneous catheter removal and a new catheter replacement are acceptable for relapsing peritonitis if the dialysate can be cleared first [<a href="#rid20">20,71,72</a>]. Simultaneous catheter replacement is not possible for refractory peritonitis, fungal peritonitis, or peritonitis associated with intra-abdominal pathology. In these settings, there should be a minimum period of three to four weeks between the time of catheter removal and new catheter placement.</p><p>Early catheter removal in patients with refractory peritonitis reduces mortality and avoids prolonged episodes of peritonitis that could damage the peritoneal membrane [<a href="#rid45">45,73</a>]. In a report describing 636 episodes of peritonitis and 16 deaths, the catheter was removed between the 5<sup>th</sup> and the 10<sup>th</sup> day in six patients who died and after 10 days in seven patients who died [<a href="#rid73">73</a>].</p><p>Limited data exist concerning success with peritoneal dialysis catheter reinsertion because of catheter removal for severe peritonitis [<a href="#rid74">74</a>]. Reported success rates range from 30 to 55 percent at follow-up of 20 to 24 months, with overall mortality of 19 to 36 percent [<a href="#rid75">75,76</a>]. Technique failure was most common in those with increased dialysis vintage.</p><p class="headingAnchor" id="H4116301054"><span class="h1">DIALYSIS PRESCRIPTION</span><span class="headingEndMark"> — </span>Because of changes in peritoneal membrane characteristics during infection, adjustments to the peritoneal dialysis prescription may be necessary. Changes sometimes made to the dialysis regimen in the setting of peritonitis are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid exchanges</strong> – If the patient is having significant pain, we perform one to two rapid in-and-out exchanges prior to the administration of antibiotics. Rapid exchanges reduce pain and may reduce the inflammatory burden and endotoxin load but have little effect on the duration of peritonitis or likelihood of cure [<a href="#rid77">77,78</a>]. If rapid exchanges are performed, dialysate containing 1.5 percent dextrose should be used so that ultrafiltration is not excessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Addition of heparin to dialysate</strong> – Heparin (500 to 1000 units/L of dialysate) may be added when fibrin strands are observed in dialysate or when there is a history of clogging of the catheter. Heparin helps to lyse and/or prevent fibrin clots [<a href="#rid78">78</a>]. Heparin is otherwise not added even if dialysate is cloudy (as it almost always is in setting of peritonitis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjustment for volume overload</strong> – Patients commonly become volume overloaded during episodes of peritonitis because there is decreased ultrafiltration. Decreased ultrafiltration is due to an increase in the solute transport rate that results in rapid equilibration of fluid and solute across the inflamed peritoneal membrane and the reabsorption of fluid from the peritoneal cavity into the blood. (See  <a class="medical medical_review" href="/d/html/1914.html" rel="external">"Management of hypervolemia in patients on peritoneal dialysis", section on 'Related to dialysis'</a>.)</p><p></p><p class="bulletIndent1">If this occurs, we adjust the dialysis prescription to treat volume overload. We use hypertonic (4.25 percent) dextrose solutions or <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> for one or two exchanges per day. We may also reduce the dwell time. Reducing the dwell time removes the fluid from the peritoneum before it can be reabsorbed. (See  <a class="medical medical_review" href="/d/html/1914.html" rel="external">"Management of hypervolemia in patients on peritoneal dialysis", section on 'Icodextrin dialysate'</a> and  <a class="medical medical_review" href="/d/html/1914.html" rel="external">"Management of hypervolemia in patients on peritoneal dialysis", section on 'Additional exchange'</a>.)</p><p></p><p class="bulletIndent1">In the absence of hypervolemia, we generally do not change the dwell time or number of exchanges. Theoretically, long dwell times (four to six hours) may be preferred to short dwell times in patients with peritonitis because they are associated with higher numbers of functional intraperitoneal macrophages and immunoglobulin G concentrations [<a href="#rid2">2,79</a>]. However, there are no conclusive data that this improves outcomes, and, as noted, long dwells may result in decreased ultrafiltration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cessation of dialysis</strong> – In general, we do not stop peritoneal dialysis in the setting of peritonitis. Early studies suggested that stopping peritoneal dialysis for 48 hours after giving one dose of antibiotics resulted in a high cure rate [<a href="#rid80">80,81</a>]. However, this approach is not favored for multiple reasons. Such patients would require hemodialysis, which is associated with additional risks associated with vascular catheter placement and the hemodialysis procedure. In addition, withholding peritoneal dialysis in patients with severe peritonitis may increase the risk of encapsulating peritoneal sclerosis [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/d/html/114179.html" rel="external">"Encapsulating peritoneal sclerosis in patients on peritoneal dialysis", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1">However, stopping peritoneal dialysis may be necessary in severe cases of peritonitis in which the catheter is removed. (See <a class="local">'Indications for catheter removal'</a> above.)</p><p></p><p class="headingAnchor" id="H258182369"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Peritonitis may lead to death, catheter removal, or switching dialysis modality. These risks are detailed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – The reported peritonitis-associated mortality is 2 to 6 percent [<a href="#rid2">2,5,51,52,83</a>]. The mortality risk is highest with fungal pathogens, gram-negative organisms, and <em>S. aureus</em> [<a href="#rid51">51,83</a>]. In one retrospective Spanish study of 565 patients (693 episodes of peritonitis), mortality rates of 28, 19, and 15 percent were associated with fungus, enteric organisms, and <em>S. aureus</em>, respectively [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1">Peritonitis is also associated with increased mortality from noninfectious causes. In a study of 1316 peritoneal dialysis patients who died while being treated with peritoneal dialysis or within 30 days of transfer to hemodialysis, there was a much greater risk of having had peritonitis within the four months prior to death compared with the rest of the year, even though the immediate cause of death was not attributed to peritonitis in the majority of cases [<a href="#rid84">84</a>]. In particular, there was a marked increase in the risk of having had peritonitis in the 30 days prior to death among patients who died of cardiovascular, cerebrovascular, or peripheral vascular disease (odds ratio 3.4, 95% CI 2.4-4.6). Similar findings were reported in a study of 1321 peritoneal dialysis patients, which found that peritonitis was independently associated with increased risks of all-cause, cardiovascular, and infection-related mortality in patients dialyzed for longer than two years [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">Secondary peritonitis is associated with a worse prognosis [<a href="#rid50">50,86,87</a>]. In one report, 11 of 26 patients with secondary peritonitis died [<a href="#rid86">86</a>] compared with an overall peritonitis-associated mortality of approximately 2 to 3 percent among all peritoneal dialysis patients with peritonitis [<a href="#rid52">52</a>]. In the study of secondary peritonitis, mortality correlated with the specific causes of peritonitis (particularly infarcted bowel), the time to diagnosis, and definitive surgical intervention. (See  <a class="medical medical_review" href="/d/html/1897.html" rel="external">"Unique aspects of gastrointestinal disease in patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1">Peritonitis due to extended-spectrum beta-lactamase (ESBL) or carbapenemase-producing gram-negative organisms is associated with higher mortality [<a href="#rid88">88</a>]. Peritonitis due to multidrug-resistant gram-negative pathogens may occur in patients who have previously received broad-spectrum antimicrobial therapy, who have resided in a long-term care facility, or who are from a region where such organisms are endemic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter removal</strong> – Most cases of peritoneal dialysis-associated peritonitis resolve with outpatient antibiotic treatment [<a href="#rid89">89</a>]. The risk of having to remove the catheter to eradicate infection is approximately 20 percent with variability between centers and with individual organisms [<a href="#rid89">89</a>]. Coagulase-negative staphylococci, streptococci, and culture-negative peritonitis have the lowest risk of failure without catheter removal (&lt;20 percent); corynebacteria, enterococci, <em>S.</em> <em>aureus</em>,<em> </em>and non-<em>Pseudomonas</em> gram-negative peritonitis have a moderate risk of requiring catheter removal (20 to 40 percent); <em>Pseudomonas </em>has the highest risk of requiring catheter removal (&gt;40 percent) [<a href="#rid89">89-92</a>].</p><p></p><p class="bulletIndent1">The risk of requiring catheter removal increases if there is a concurrent exit-site or tunnel infection [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfer to hemodialysis</strong> – Peritonitis results in a 5 to 20 percent risk of patients needing to switch to hemodialysis [<a href="#rid51">51,89-92,94,95</a>]. Organisms that are considered moderate or high risk for requiring catheter removal (corynebacteria, enterococci, <em>S. aureus</em> and non-<em>Pseudomonas</em> gram-negatives, fungus, and <em>Pseudomonas</em>) are associated with higher risk of switching to hemodialysis compared with coagulase-negative <em>Staphylococcus</em>, <em>Streptococcus</em>, and culture-negative peritonitis [<a href="#rid89">89-92</a>].</p><p></p><p class="headingAnchor" id="H2488356071"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H13323595"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4426.html" rel="external">"Patient education: Peritoneal dialysis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15501152"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Peritonitis is a major complication of peritoneal dialysis and is the primary reason patients switch from peritoneal dialysis to hemodialysis. The majority of peritonitis cases are caused by bacteria; a small percentage of cases are caused by fungi, mostly <em>Candida</em> spp. (See <a class="local">'Introduction'</a> above and <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment for peritoneal dialysis-associated peritonitis consists of prompt antimicrobial therapy  (<a class="graphic graphic_algorithm graphicRef143367" href="/d/graphic/143367.html" rel="external">algorithm 1</a>); in some cases, catheter removal is also warranted. Additional therapies may include the addition of heparin to dialysate and rapid exchanges to reduce symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial empiric antimicrobial therapy</strong> – For most patients with peritoneal dialysis-associated peritonitis, we suggest initial combination therapy with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> rather than with other antibiotic regimens  (<a class="graphic graphic_table graphicRef143362" href="/d/graphic/143362.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The initial empiric antibiotic regimen should cover gram-positive and gram-negative organisms, should be based on local susceptibility data, and should account for any recent antimicrobial therapy or culture results. Intraperitoneal administration of antibiotics is preferred to intravenous administration unless the patient appears septic. (See <a class="local">'Route of administration'</a> above and <a class="local">'Initial empiric therapy'</a> above.)</p><p></p><p class="bulletIndent2">The initial antibiotic regimen should be adjusted based on culture and sensitivity data. (See <a class="local">'Subsequent therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Polymicrobial peritonitis</strong> – Peritonitis due to multiple enteric organisms or mixed gram-negative/gram-positive organisms should raise concern for a concurrent intra-abdominal condition such as ischemic bowel or diverticular disease. (See <a class="local">'Polymicrobial peritonitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Culture-negative peritonitis</strong> – Culture-negative peritonitis should be initially treated with empiric antibiotic therapy that covers both gram-positive and negative organisms. A repeat cell count and culture should be obtained after three days of empiric therapy to determine further management  (<a class="graphic graphic_algorithm graphicRef143363" href="/d/graphic/143363.html" rel="external">algorithm 5</a>). (See <a class="local">'Culture-negative peritonitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for catheter removal</strong> – Indications for catheter removal include the following (see <a class="local">'Indications for catheter removal'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Refractory peritonitis </p><p class="bulletIndent3"><span class="glyph">-</span>Relapsing peritonitis </p><p class="bulletIndent3"><span class="glyph">-</span>Peritonitis caused by fungal organisms (see  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Peritonitis occurring in association with intra-abdominal pathology, such as an abscess, perforation, or infarcted bowel</p><p class="bulletIndent3"><span class="glyph">-</span>Culture-negative peritonitis with persistent symptoms and/or high peritoneal white blood cell count</p><p></p><p class="bulletIndent2">We also remove the catheter for peritonitis due to specific bacteria that are difficult to treat and are associated with high mortality. For patients with peritoneal dialysis-associated peritonitis due to <em>Mycobacteria</em> or <em>Nocardia</em> spp, we suggest catheter removal and antimicrobial therapy rather than antimicrobial therapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most episodes of peritoneal dialysis-associated peritonitis resolve with outpatient antibiotic treatment. Approximately 20 percent require catheter removal to eradicate infection. There is a reported associated mortality of 2 to 6 percent. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Holley JL, Praino BM. Complications of peritoneal dialysis: Diagnosis and management. Semin Dial 1990; 3:245.</a></li><li><a class="nounderline abstract_t">Stablein DM, Nolph KD, Lindblad AS. Timing and characteristics of multiple peritonitis episodes: a report of the National CAPD Registry. Am J Kidney Dis 1989; 14:44.</a></li><li><a class="nounderline abstract_t">Port FK, Held PJ, Nolph KD, et al. Risk of peritonitis and technique failure by CAPD connection technique: a national study. Kidney Int 1992; 42:967.</a></li><li><a class="nounderline abstract_t">Kim DK, Yoo TH, Ryu DR, et al. Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. Perit Dial Int 2004; 24:424.</a></li><li><a class="nounderline abstract_t">Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 2006; :S55.</a></li><li><a class="nounderline abstract_t">Lewis SL. Recurrent peritonitis: evidence for possible viral etiology. Am J Kidney Dis 1991; 17:343.</a></li><li><a class="nounderline abstract_t">Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 2005; 45:372.</a></li><li><a class="nounderline abstract_t">Kan GW, Thomas MA, Heath CH. A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: is empiric vancomycin still indicated for some patients? Perit Dial Int 2003; 23:465.</a></li><li><a class="nounderline abstract_t">Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002). Nephrol Dial Transplant 2004; 19:2584.</a></li><li><a class="nounderline abstract_t">Whitty R, Bargman JM, Kiss A, et al. Residual Kidney Function and Peritoneal Dialysis-Associated Peritonitis Treatment Outcomes. Clin J Am Soc Nephrol 2017; 12:2016.</a></li><li><a class="nounderline abstract_t">Bunke M, Brier ME, Golper TA. Culture-negative CAPD peritonitis: the Network 9 Study. Adv Perit Dial 1994; 10:174.</a></li><li><a class="nounderline abstract_t">Burkart JM, Hylander B, Durnell-Figel T, Roberts D. Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10:41.</a></li><li><a class="nounderline abstract_t">Grützmacher P, Tsobanelis T, Bruns M, et al. Decrease in peritonitis rate by integrated disconnect system in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 Suppl 2:S326.</a></li><li><a class="nounderline abstract_t">Troidle L, Kliger AS, Gorban-Brennan N, et al. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996; 50:1368.</a></li><li><a class="nounderline abstract_t">Wood CJ, Fleming V, Turnidge J, et al. Campylobacter peritonitis in continuous ambulatory peritoneal dialysis: report of eight cases and a review of the literature. Am J Kidney Dis 1992; 19:257.</a></li><li><a class="nounderline abstract_t">Holley JL, Bernardini J, Piraino B. Polymicrobial peritonitis in patients on continuous peritoneal dialysis. Am J Kidney Dis 1992; 19:162.</a></li><li><a class="nounderline abstract_t">Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Perit Dial Int 2003; 23:456.</a></li><li><a class="nounderline abstract_t">Ballinger AE, Palmer SC, Wiggins KJ, et al. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev 2014; :CD005284.</a></li><li><a class="nounderline abstract_t">Wiggins KJ, Johnson DW, Craig JC, Strippoli GF. Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis 2007; 50:967.</a></li><li><a class="nounderline abstract_t">Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.</a></li><li><a class="nounderline abstract_t">Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393.</a></li><li><a class="nounderline abstract_t">Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42:110.</a></li><li><a class="nounderline abstract_t">Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31:614.</a></li><li><a class="nounderline abstract_t">Wong PN, Lo KY, Tong GM, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. Perit Dial Int 2007; 27:531.</a></li><li><a class="nounderline abstract_t">Záruba K, Peters J, Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. Am J Kidney Dis 1991; 17:43.</a></li><li><a class="nounderline abstract_t">Robitaille P, Mérouani A, Clermónt MJ, Hébert E. Successful antifungal prophylaxis in chronic peritoneal dialysis: a pediatric experience. Perit Dial Int 1995; 15:77.</a></li><li><a class="nounderline abstract_t">Wadhwa NK, Suh H, Cabralda T. Antifungal prophylaxis for secondary fungal peritonitis in peritoneal dialysis patients. Adv Perit Dial 1996; 12:189.</a></li><li><a class="nounderline abstract_t">Lo WK, Chan CY, Cheng SW, et al. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28:549.</a></li><li><a class="nounderline abstract_t">Thodis E, Vas SI, Bargman JM, et al. Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18:583.</a></li><li><a class="nounderline abstract_t">Williams PF, Moncrieff N, Marriott J. No benefit in using nystatin prophylaxis against fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20:352.</a></li><li><a class="nounderline abstract_t">Moreiras-Plaza M, Vello-Román A, Sampróm-Rodríguez M, Feijóo-Piñeiro D. Ten years without fungal peritonitis: a single center's experience. Perit Dial Int 2007; 27:460.</a></li><li><a class="nounderline abstract_t">Lye WC. Empirical treatment of CAPD peritonitis: to each his own? Perit Dial Int 2004; 24:416.</a></li><li><a class="nounderline abstract_t">Van Biesen W, Vanholder R, Vogelaers D, et al. The need for a center-tailored treatment protocol for peritonitis. Perit Dial Int 1998; 18:274.</a></li><li><a class="nounderline abstract_t">Muthucumarana K, Howson P, Crawford D, et al. The Relationship Between Presentation and the Time of Initial Administration of Antibiotics With Outcomes of Peritonitis in Peritoneal Dialysis Patients: The PROMPT Study. Kidney Int Rep 2016; 1:65.</a></li><li><a class="nounderline abstract_t">Teitelbaum I. Vancomycin for the initial therapy of peritonitis: don't throw out the baby with the bathwater. Perit Dial Int 2001; 21:235.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol 2007; 2:245.</a></li><li><a class="nounderline abstract_t">Govindarajulu S, Hawley CM, McDonald SP, et al. Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. Perit Dial Int 2010; 30:311.</a></li><li><a class="nounderline abstract_t">Kitrungphaiboon T, Puapatanakul P, Chuengsaman P, et al. Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial. Am J Kidney Dis 2019; 74:601.</a></li><li><a class="nounderline abstract_t">Wong KM, Chan YH, Cheung CY, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 2001; 38:127.</a></li><li><a class="nounderline abstract_t">Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133.</a></li><li><a class="nounderline abstract_t">Flanigan MJ, Lim VS. Initial treatment of dialysis associated peritonitis: a controlled trial of vancomycin versus cefazolin. Perit Dial Int 1991; 11:31.</a></li><li><a class="nounderline abstract_t">Gucek A, Bren AF, Hergouth V, Lindic J. Cefazolin and netilmycin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis. Adv Perit Dial 1997; 13:218.</a></li><li><a class="nounderline abstract_t">Khairullah Q, Provenzano R, Tayeb J, et al. Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients. Perit Dial Int 2002; 22:339.</a></li><li><a class="nounderline abstract_t">Kussmann M, Schuster L, Zeitlinger M, et al. The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis. Eur J Clin Microbiol Infect Dis 2015; 34:2257.</a></li><li><a class="nounderline abstract_t">Siva B, Hawley CM, McDonald SP, et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin J Am Soc Nephrol 2009; 4:957.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Leung CB, et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int 2001; 59:2309.</a></li><li><a class="nounderline abstract_t">Dos Santos ACML, Hernandes RT, Montelli AC, et al. Clinical and microbiological factors predicting outcomes of nonfermenting gram-negative bacilli peritonitis in peritoneal dialysis. Sci Rep 2021; 11:12248.</a></li><li><a class="nounderline abstract_t">Tzanetou K, Triantaphillis G, Tsoutsos D, et al. Stenotrophomonas maltophilia peritonitis in CAPD patients: susceptibility to antibiotics and treatment outcome: a report of five cases. Perit Dial Int 2004; 24:401.</a></li><li><a class="nounderline abstract_t">Szeto CC, Li PK, Leung CB, et al. Xanthomonas maltophilia peritonitis in uremic patients receiving continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1997; 29:91.</a></li><li><a class="nounderline abstract_t">Kern EO, Newman LN, Cacho CP, et al. Abdominal catastrophe revisited: the risk and outcome of enteric peritoneal contamination. Perit Dial Int 2002; 22:323.</a></li><li><a class="nounderline abstract_t">Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52:524.</a></li><li><a class="nounderline abstract_t">Ghali JR, Bannister KM, Brown FG, et al. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. Perit Dial Int 2011; 31:651.</a></li><li><a class="nounderline abstract_t">de Freitas DG, Gokal R. Sterile peritonitis in the peritoneal dialysis patient. Perit Dial Int 2005; 25:146.</a></li><li><a class="nounderline abstract_t">Sewell DL, Golper TA, Hulman PB, et al. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate. Perit Dial Int 1990; 10:49.</a></li><li><a class="nounderline abstract_t">Seow YY, Iles-Smith H, Hirst H, Gokal R. Icodextrin-associated peritonitis among CAPD patients. Nephrol Dial Transplant 2003; 18:1951.</a></li><li><a class="nounderline abstract_t">Borràs M, Martin M, Fernández E. Sterile peritonitis outbreak related to icodextrin treatment. Perit Dial Int 2004; 24:87.</a></li><li><a class="nounderline abstract_t">Mangram AJ, Archibald LK, Hupert M, et al. Outbreak of sterile peritonitis among continuous cycling peritoneal dialysis patients. Kidney Int 1998; 54:1367.</a></li><li><a class="nounderline abstract_t">MacGinley R, Cooney K, Alexander G, et al. Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. Am J Kidney Dis 2002; 40:1030.</a></li><li><a class="nounderline abstract_t">Foggensteiner L, Baylis J, Moss H, Williams P. Timely initiation of dialysis--single-exchange experience in 39 patients starting peritoneal dialysis. Perit Dial Int 2002; 22:471.</a></li><li><a class="nounderline abstract_t">Tintillier M, Pochet JM, Christophe JL, et al. Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review. Perit Dial Int 2002; 22:534.</a></li><li><a class="nounderline abstract_t">Touré F, Lavaud S, Mohajer M, et al. Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis. Kidney Int 2004; 65:654.</a></li><li><a class="nounderline abstract_t">Boer WH, Vos PF, Fieren MW. Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis. Perit Dial Int 2003; 23:33.</a></li><li><a class="nounderline abstract_t">Glorieux G, Lameire N, Van Biesen W, et al. Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids. Nephrol Dial Transplant 2003; 18:1648.</a></li><li><a class="nounderline abstract_t">Chow KM, Szeto CC, Cheung KK, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis. Clin J Am Soc Nephrol 2006; 1:768.</a></li><li><a class="nounderline abstract_t">Tantiyavarong P, Traitanon O, Chuengsaman P, et al. Dialysate White Blood Cell Change after Initial Antibiotic Treatment Represented the Patterns of Response in Peritoneal Dialysis-Related Peritonitis. Int J Nephrol 2016; 2016:6217135.</a></li><li><a class="nounderline abstract_t">Xu R, Chen Y, Luo S, et al. Clinical characteristics and outcomes of peritoneal dialysis-related peritonitis with different trends of change in effluent white cell count: a longitudinal study. Perit Dial Int 2013; 33:436.</a></li><li><a class="nounderline abstract_t">Fish R, Nipah R, Jones C, et al. Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levels. Perit Dial Int 2012; 32:332.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow VC, Chow KM, et al. Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. Kidney Int 2006; 69:1245.</a></li><li><a class="nounderline abstract_t">Jain AK, Blake PG. Non-Pseudomonas Gram-negative peritonitis. Kidney Int 2006; 69:1107.</a></li><li><a class="nounderline abstract_t">Thomson BKA, Vaughan S, Momciu B. Mycobacterium tuberculosis peritonitis in peritoneal dialysis patients: A scoping review. Nephrology (Carlton) 2022; 27:133.</a></li><li><a class="nounderline abstract_t">Mitra A, Teitelbaum I. Is it safe to simultaneously remove and replace infected peritoneal dialysis catheters? Review of the literature and suggested guidelines. Adv Perit Dial 2003; 19:255.</a></li><li><a class="nounderline abstract_t">Singhal MK, Vas SI, Oreopoulos DG. Treatment of peritoneal dialysis catheter-related infections by simultaneous catheter removal and replacement. Is it safe? Perit Dial Int 1998; 18:565.</a></li><li><a class="nounderline abstract_t">Digenis GE, Abraham G, Savin E, et al. Peritonitis-related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1990; 10:45.</a></li><li><a class="nounderline abstract_t">Pérez-Fontán M, Rodríguez-Carmona A. Peritoneal catheter removal for severe peritonitis: landscape after a lost battle. Perit Dial Int 2007; 27:155.</a></li><li><a class="nounderline abstract_t">Cox SD, Walsh SB, Yaqoob MM, Fan SL. Predictors of survival and technique success after reinsertion of peritoneal dialysis catheter following severe peritonitis. Perit Dial Int 2007; 27:67.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Wong TY, et al. Feasibility of resuming peritoneal dialysis after severe peritonitis and Tenckhoff catheter removal. J Am Soc Nephrol 2002; 13:1040.</a></li><li><a class="nounderline abstract_t">Zelenitsky S, Barns L, Findlay I, et al. Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 2000; 36:1009.</a></li><li><a class="nounderline abstract_t">Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs 2002; 25:249.</a></li><li><a class="nounderline abstract_t">Vlaanderen K, Bos HJ, de Fijter CW, et al. Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients. Nephron 1991; 57:29.</a></li><li><a class="nounderline abstract_t">Cairns HS, Beckett J, Rudge CJ, et al. Treatment of resistant CAPD peritonitis by temporary discontinuation of peritoneal dialysis. Clin Nephrol 1989; 32:27.</a></li><li><a class="nounderline abstract_t">Pagniez DC, MacNamara E, Fortin F, et al. Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis. BMJ 1988; 297:1174.</a></li><li><a class="nounderline abstract_t">Burkart JM. Short, long, or no dwells for PD-associated peritonitis. Semin Dial 1998; 11:257.</a></li><li><a class="nounderline abstract_t">Pérez Fontan M, Rodríguez-Carmona A, García-Naveiro R, et al. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25:274.</a></li><li><a class="nounderline abstract_t">Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 2012; 23:1398.</a></li><li><a class="nounderline abstract_t">Ye H, Zhou Q, Fan L, et al. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. BMC Nephrol 2017; 18:186.</a></li><li><a class="nounderline abstract_t">Tzamaloukas AH, Murata GH, Fox L. Peritoneal catheter loss and death in continuous ambulatory peritoneal dialysis peritonitis: correlation with clinical and biochemical parameters. Perit Dial Int 1993; 13 Suppl 2:S338.</a></li><li><a class="nounderline abstract_t">Harwell CM, Newman LN, Cacho CP, et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int 1997; 17:586.</a></li><li><a class="nounderline abstract_t">Yip T, Tse KC, Lam MF, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients. Perit Dial Int 2006; 26:191.</a></li><li><a class="nounderline abstract_t">Htay H, Cho Y, Pascoe EM, et al. Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. Am J Kidney Dis 2018; 71:814.</a></li><li><a class="nounderline abstract_t">O'Shea S, Hawley CM, McDonald SP, et al. Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. BMC Nephrol 2009; 10:19.</a></li><li><a class="nounderline abstract_t">Cho Y, Badve SV, Hawley CM, et al. Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. Nephrol Dial Transplant 2014; 29:1940.</a></li><li><a class="nounderline abstract_t">Gregory MC, Duffy DP. Toxic shock following staphylococcal peritonitis. Clin Nephrol 1983; 20:101.</a></li><li><a class="nounderline abstract_t">Millikin SP, Matzke GR, Keane WF. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1991; 11:252.</a></li><li><a class="nounderline abstract_t">Guo A, Mujais S. Patient and technique survival for patients on PD in the US in large national cohorts. Kidney Int 2003; 64:S3.</a></li><li><a class="nounderline abstract_t">Pulliam J, Li NC, Maddux F, et al. First-year outcomes of incident peritoneal dialysis patients in the United States. Am J Kidney Dis 2014; 64:761.</a></li></ol></div><div id="topicVersionRevision">Topic 1882 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Complications of peritoneal dialysis: Diagnosis and management</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2741935" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Timing and characteristics of multiple peritonitis episodes: a report of the National CAPD Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453589" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk of peritonitis and technique failure by CAPD connection technique: a national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15490981" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080112" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Microbiology and outcomes of peritonitis in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1847581" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrent peritonitis: evidence for possible viral etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685516" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14604199" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: is empiric vancomycin still indicated for some patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304559" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Peritoneal dialysis-associated peritonitis in Scotland (1999-2002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114005" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Residual Kidney Function and Peritoneal Dialysis-Associated Peritonitis Treatment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7999821" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Culture-negative CAPD peritonitis: the Network 9 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2085581" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399600" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Decrease in peritonitis rate by integrated disconnect system in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8887301" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1553971" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Campylobacter peritonitis in continuous ambulatory peritoneal dialysis: report of eight cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739099" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polymicrobial peritonitis in patients on continuous peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14604197" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771351" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment for peritoneal dialysis-associated peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037098" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15796137" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Peritoneal dialysis-related infections recommendations: 2005 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628102" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Peritoneal dialysis-related infections recommendations: 2010 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35264029" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880990" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ISPD position statement on reducing the risks of peritoneal dialysis-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704443" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1986569" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7734569" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful antifungal prophylaxis in chronic peritoneal dialysis: a pediatric experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8865899" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antifungal prophylaxis for secondary fungal peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840945" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932656" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898060" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : No benefit in using nystatin prophylaxis against fungal peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602157" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ten years without fungal peritonitis: a single center's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15490979" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Empirical treatment of CAPD peritonitis: to each his own?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663891" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The need for a center-tailored treatment protocol for peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142915" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Relationship Between Presentation and the Time of Initial Administration of Antibiotics With Outcomes of Peritonitis in Peritoneal Dialysis Patients: The PROMPT Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11475337" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Vancomycin for the initial therapy of peritonitis: don't throw out the baby with the bathwater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699420" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190031" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31331757" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431192" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20034345" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2049420" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Initial treatment of dialysis associated peritonitis: a controlled trial of vancomycin versus cefazolin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360685" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cefazolin and netilmycin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12227391" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26337433" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406972" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380835" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34112833" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical and microbiological factors predicting outcomes of nonfermenting gram-negative bacilli peritonitis in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15335157" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Stenotrophomonas maltophilia peritonitis in CAPD patients: susceptibility to antibiotics and treatment outcome: a report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9002535" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Xanthomonas maltophilia peritonitis in uremic patients receiving continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12227389" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Abdominal catastrophe revisited: the risk and outcome of enteric peritoneal contamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264012" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719685" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15796141" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sterile peritonitis in the peritoneal dialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2128189" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of large volume culture to other methods for isolation of microorganisms from dialysate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937264" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Icodextrin-associated peritonitis among CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15104347" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sterile peritonitis outbreak related to icodextrin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767557" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Outbreak of sterile peritonitis among continuous cycling peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407649" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12322818" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Timely initiation of dialysis--single-exchange experience in 39 patients starting peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12322832" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717938" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12691504" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897108" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699285" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27656294" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dialysate White Blood Cell Change after Initial Antibiotic Treatment Represented the Patterns of Response in Peritoneal Dialysis-Related Peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23733659" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical characteristics and outcomes of peritoneal dialysis-related peritonitis with different trends of change in effluent white cell count: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045102" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: correlation with serum levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467787" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572185" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Non-Pseudomonas Gram-negative peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34743395" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mycobacterium tuberculosis peritonitis in peritoneal dialysis patients: A scoping review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14763074" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Is it safe to simultaneously remove and replace infected peritoneal dialysis catheters? Review of the literature and suggested guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932653" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment of peritoneal dialysis catheter-related infections by simultaneous catheter removal and replacement. Is it safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2085582" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Peritonitis-related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299150" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Peritoneal catheter removal for severe peritonitis: landscape after a lost battle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179514" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Predictors of survival and technique success after reinsertion of peritoneal dialysis catheter following severe peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912264" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Feasibility of resuming peritoneal dialysis after severe peritonitis and Tenckhoff catheter removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054358" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12027134" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Peritonitis in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2046812" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2489022" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Treatment of resistant CAPD peritonitis by temporary discontinuation of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3144336" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Short, long, or no dwells for PD-associated peritonitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15981776" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626818" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28583107" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399604" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Peritoneal catheter loss and death in continuous ambulatory peritoneal dialysis peritonitis: correlation with clinical and biochemical parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655159" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623424" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29289475" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19631002" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24596083" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6616974" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Toxic shock following staphylococcal peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1832968" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Patient and technique survival for patients on PD in the US in large national cohorts</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24927898" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : First-year outcomes of incident peritoneal dialysis patients in the United States.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
